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Abstract: Oxysterols are metabolites produced in the first step of cholesterol metabolism, which
is related to neurodegenerative disorder. They can be detected by testing blood, plasma,
serum, or cerebrospinal fluid. In this study, some cholesterol precursors and oxysterols were
determined by gas chromatography coupled to mass spectrometry. The selected cholesterol-related
compounds were desmosterol, lathosterol, lanosterol, 7α-hydroxycholesterol, 7β-hydroxycholesterol,
24(S)-hydroxycholesterol, 25-hydroxycholesterol, 7-ketocholesterol, and 27-hydroxycholesterol.
A powerful method was developed and validated considering various analytical parameters,
such as linearity index, detection and quantification limits, selectivity and matrix effect,
precision (repeatability), and trueness (recovery factor) for each cholesterol-related compound.
7α-hydroxycholesterol, 7β-hydroxycholesterol, and desmosterol exhibited the lowest detection and
quantification limits, with 0.01 and 0.03 µg/mL, respectively, in the three cases. 7-ketocholesterol and
lathosterol showed matrix effect percentages between 95.5% and 104.8%, respectively (demonstrating
a negligible matrix effect), and very satisfactory repeatability values (i.e., overall performance of
the method). Next, the method was applied to the analysis of a very interesting selection of mouse
plasma samples (9 plasma extracts of non-transgenic and transgenic mice that had been fed different
diets). Although the number of samples was limited, the current study led to some biologically
relevant conclusions regarding brain cholesterol metabolism.
Keywords: cholesterol-related compounds; GC-(IT)MS; selected ion monitoring mode
1. Introduction
Oxysterols play a crucial role as (a) regulators of expression of genes involved in lipid and sterol
biosynthesis; (b) substrates for the formation of bile acids; and (c) mediators of reverse cholesterol
transport, through which excess cholesterol is returned to the liver for excretion [1,2]. However, an
overabundance of oxysterols can cause several diseases, such as cardiovascular disease, retina
degeneration, inflammatory bowel disease, atherosclerosis, and neurodegenerative disorders [3–5].
Oxysterols can be found in several chemical forms and are enzymatically produced in the first
steps of cholesterol (Chol) metabolism [6,7]. For example, Alzheimer’s disease (AD) pathology is
initiated (or accelerated) by a deregulation of the metabolism of Chol, sphingolipids, and fatty acids;
in fact, hypercholesterolemia is an important risk factor for AD [8,9]. These metabolites are present
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in blood (serum or plasma), cerebrospinal fluid and brain tissues. Desmosterol, lanosterol, and
lathosterol are the precursors of Chol synthesis. Chol is metabolized into side chain oxysterols
(24(S)-hydroxycholesterol, 25-hydroxycholesterol, and 27-hydroxycholesterol) during its hepatic
conversion [10] and transported into the brain by apolipoprotein E. Under normal conditions, no
exchange of cholesterol occurs over the blood-brain barrier. However, Chol can be transported to
the human brain in the form of a side-chain oxidized oxysterol such as 24(S)-hydroxycholesterol and
27-hydroxycholesterol [5,11,12]. As a consequence, the presence of these oxysterols has been related to
neurological disorders and such oxysterols have been proposed as potential AD biomarkers [9,13].
Over the last decades, significant scientific developments and cutting-edge technologies have
enabled a technological revolution in molecular biological methods. Metabolomics is a field that deals
with the study of metabolites, which are the final products of cell regulation processes due to responses
to genetic and environmental changes in biological systems [14].
Different approaches can be used in metabolomics [15]. Metabolite targeted analysis, for example,
involves the detection, identification, and quantification of a single metabolite or a small group of
specific metabolites of particular importance. The comprehensive characterization of a group of
metabolites in an organism, tissue or cell implies the use of advanced analytical techniques. Oxysterols
have been determined so far by liquid chromatography (LC) or gas chromatography (GC), mainly
coupled to mass spectrometry (MS) and also by nuclear magnetic resonance (NMR) [6,16]. MS and
NMR have a great potential to select proper biomarkers in order to diagnose associated diseases [13,17].
To determine the oxysterols present in biological fluids and tissues, there are different ways to
carry out the sample preparation that obviously depend on the matrix, analyte/s and technique/s
to be used. Blood plasma has been separated from blood serum by using ethylenediaminetetraacetic
acid (EDTA) and further centrifugating the blood sample [18,19]. Next, sterols can be extracted from
blood plasma by alkaline hydrolysis. This leads to the degradation of lipids such as phospholipids and
triglycerides and avoids their potential interferences. Finally, solid phase extraction (SPE) has been
utilized to separate sterols from other substances [18,20].
A derivatization reaction is usually required prior to GC analysis in order to increase the volatility
of oxysterols; N,O-bis(trimethylsilyl)trifluoracetamide/trimethylchloroside (BSTFA:TMCS) is a very
widely used derivatization reagent. However, N-methyl-N-(trimethylsilyl)-trifluoroacetamide-1,4-
dithioerythritol-trimethyliodosilane (MSTFA:DTE:TMIS) has been proposed as one of the most efficient
derivatization reagents based on its specificity/sensitivity ratio in GC-MS [21,22].
LC is recognized as a chromatographic technique that does not require a previous derivatization
of the samples. Yet, in the specific case of determining oxysterols, the quantification can be more
difficult if the analytes are not derivatized [22]. The use of N,N-dimethyl-glycine, picolinyl esters, and
Girard P reagents has been described in LC-MS [23,24]. The derivatized compounds are more polar
than the native sterols, which improves the ionization in the MS system. In fact, the number of papers
describing LC-MS analytical methodologies for oxysterol determination in biological matrices has
lately increased [25–27].
Traditionally, the instrumental analysis of sterols and related compounds in plasma has used GC
and GC-MS [18]. Although GC and its use coupled to MS have some limitations, these techniques
are widely used for sterol analysis due to their chromatographic resolving capacity, their robustness,
and the relatively low cost of acquiring and operating the instruments [6,19,20,28]. GC-MS with
electron ionization provides spectra rich in structural information, allowing the determination of
unknown compounds [29]. By contrast, LC-MS requires Girard P derivatizations and exploring the
mass-load ratio with the MS3 mode in order to obtain structural information and identify unexpected
oxysterols [27]. The use of MS in tandem (MSn) can improve the sensitivity of the methods [30,31], but
can also entail some methodological difficulties. A review conducted by Griffiths and Wang in 2009 [32]
explained the biological importance of oxysterols and various relevant samples of brain and body
fluids analyzed with GC-MS and LC-MS/MS. In 2016, both authors with other colleagues presented a
review of MS-based methods for oxysterol analysis paying particular attention to LC-MS [27].
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The aim of the present study was to develop a reliable and fit-for-purpose bioanalytical method
for the determination of some Chol-related compounds (selected as potential biomarkers of AD
by the biotechnology-based company Neuron Bio) in mouse plasma from six APPswe mice and
three non-transgenic littermate mice of both sexes that were fed different diets from the age of
9 months to the age of 15 months. The analytical method was developed by using GC-MS in selected
ion monitoring (SIM) mode. An ion trap (IT) mass analyzer was used to obtain the m/z signal
of the analytes under study (7α-hydroxycholesterol (7αOHChol), desmosterol (Desm), lathosterol
(Latho), 7β-hydroxycholesterol (7βOHChol), lanosterol (Lano), 24(S)-hydroxycholesterol (24OHChol),
25-hydroxycholesterol (25OHChol), 7-ketocholesterol (7KetoChol), and 27-hydroxycholesterol
(27OHChol)) applying an MS method with 9 different segments. In other words, we defined specific
segments or analytical windows with different MS conditions in order to selectively determine each
compound. This strategy enabled us to detect and quantify Chol-related compounds with a similar
structure in mouse plasma. The potential interfering effect produced by high concentrations of
cholesterol was avoided by applying the SIM strategy.
2. Materials and Methods
2.1. Chemicals and Reagents
(HPLC)-grade methanol and ethyl acetate (EA) were provided by Panreac, Spain. BSTFA (N,O-bis
(trimethylsilyl)trifluoracetamide) with 1% TMCS (trimethylchloroside) was obtained from
Sigma-Aldrich, St. Louis, MO, USA, as a derivatization reagent. Solid standards of analytes
were supplied by Enzo Life Sciences, Farmingdale, NY, USA (24OHChol, >98%), MP Biomedicals,
Illkirch-Graffenstaden, Strasbourg, France (25OHChol, >98%), Sigma-Aldrich, St. Louis, MO, USA
(Chol, ≥99%; Latho, ≥93%; Desm, ≥84%; and 7KetoChol, ≥90%), and Avanti Polar Lipids, Alabaster,
AL, USA (Lano, >99%; 7αOHChol, >99%; 7βOHChol, >99%; and 27OHChol, >99%). In addition, 98%
purity betulin supplied by Avanti Polar Lipids, Alabaster, AL, USA, was used as internal standard (IS).
All these chemical compounds as well their corresponding solutions were stored in the dark at −20 ◦C.
Betulin was chosen as internal standard because it is not a naturally occurring sterol in blood.
This analyte has been also used as IS in other similar applications [33,34].
2.2. Standard Solutions
A multi-standard stock solution containing 100 µg/mL of each analyte (Chol, Desm, Lano, Latho,
7KetoOH, 7αOHChol, 7βOHChol, 24OHChol, 25OHChol, and 27OHChol) was prepared in methanol
weighing the appropriate amount of the solid pure standards. A 100 µg/mL stock standard solution of
betulin was also prepared in methanol.
2.3. Samples and Sample Preparation
The study was performed with two sample groups: (i) mice blood plasma as test samples and
(ii) goat blood serum as quality control samples.
Each extract was prepared applying the following procedure: 200 µL of sample were poured into
a glass tube along with 40 µL of internal standard and 0.5 mL of EA. The tube was shaken in a vortex
mixer (1 min), sonicated (50 W) for 15 min, and centrifuged for 5 min at 10,000 rpm (approx. 8400 g).
Subsequently, 100 µL of the organic phase were transferred to an Eppendorf vial and stored in the dark
at −20 ◦C until the analysis was performed.
The final concentration of IS was 40 µg/mL in all the extracts. The solvent was evaporated with
N2 and an aliquot of 50 µL of derivatization reagent was added after that. The reaction mixture was
left at room temperature for 1 h (this was previously optimized by our team and it was proved that the
total derivatization of the compounds of interest was achieved). In every case, 50 µL of the derivatized
sample extract were transferred to a chromatographic vial containing a 250 µL insert.
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(i) Mouse plasma as test samples
Six 9-month-old APPswe (transgenic) mice and three 9-month-old non-transgenic (Non-Tg)
littermate mice of both sexes were used. They were kept in temperature- and light-controlled rooms
in Neuron Bio facilities. Three APPswe mice were fed with NST0037 (a novel statin developed by
Neuron Bio (Granada, Spain) [35])—enriched diet until the age of 15 months; the rest—three APPswe
and three Non-Tg littermate mice—were fed with a control diet from until the same age. In the rest of
the paper, each type of mice will be denoted by using letters A, B and C: A are non-transgenic mice,
Non-Tg; B are transgenic mice, APPswe; and C are transgenic mice, APPswe, fed with NST0037.
The 15-month-old mice were anesthetized with sodium pentobarbital (300 mg/kg); their blood
was collected and the plasma was obtained and frozen at −80 ◦C.
(ii) Goat serum as quality control samples
The set of quality control samples was composed of 5 extracts of the blood serum of a single
goat in EA. Each extract (300 µL) was prepared in the same way as the test samples, starting from
600 µL of blood sample. As indicated above, the extracts were stored in the dark at −20 ◦C until the
analysis took place. It should be noted that the sample treatment removes the proteins; thus, extracts
from matrices of plasma and serum are quite similar and serum samples can be used as representative
examples of plasma samples for an effective analytical quality control.
Quality control (QC) standard solutions were prepared by adding 0.5, 1.0, 2.5, and 5.0 µg/mL of
each analyte into goat serum extracts. In order to effectively monitor the analytical method, two types
of QC samples were used: some were spiked before and others were spiked after the extraction.
An overall diagram showing the preparation of both sample groups (i.e., test samples and quality
control samples) is shown in Figure 1.
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Figure 1. Diagram of the preparation of (a) test samples and (b) quality control samples. The sample
code was indicated in every vial. The sample codes for the test samples (T) include information about
the type of mice (A, B, or C) and the specimen number (1, 2, or 3). The codes of the quality control
samples (QC) indicate the spiked concentration (50, 25, 10, 05, or 00) in µg/ L. (EA: ethyl acetate; IS:
internal standard; BSTFA/T S: silylation reagent).
2.4. GC-(EI/IT)MS Instrument and Method Conditions
All separations were performed by using a Varian GC 3800 gas chromatograph (Palo Alto, CA,
USA) equipped with a split/splitless injector. The GC system was coupled to a Varian (IT)MS 4000 (ion
trap) mass spectrometer (Palo Alto, CA, USA) equipped with an electron impact (EI) source. 1 µL of
each sample was introduced into the GC equipment using a robotized autosampler module (CombiPal,
CTC ANALYTICS, Zwingen, Switzerland). Splitless injection mode was selected and the injector
temperature was held at 250 ◦C.
The analytical column was a capillary column coated with a 5% diphenyl-95% dimethyl
polysiloxane stationary phase (DB-5MS; 30 m × 0.25 mm i.d. × 0.25 µm film thickness (Agilent
Technologies J&W, Santa Clara, CA, USA). A silica deactivated pre-column (1 m × 0.25 mm i.d.) with
press-fit connections (Agilent Technologies, Santa Clara, CA, USA) was used.
At the beginning of the runs, the column oven temperature was held at 200 ◦C for 0.5 min, then
programmed to increase by 20 ◦C/min up to 300 ◦C and maintained at that value for 10 min, with
a total run time of 15.50 min. Helium (99.995%) was used as the carrier gas and its flow rate was
1.2 mL/min. This method was a modification of a previously published method [21,36].
The MS conditions were as follows: the ion source temperature was held at 250 ◦C during the
GC-MS runs. The transfer-line temperature was maintained at 280 ◦C. The electron energy was 70 eV
and the emission current 10 µA. In full-scan mode, average spectra were acquired in the m/z range of
50–600 m/z and were recorded at a scan speed of 1.20 s. Scan control, data acquisition, and processing
were performed using MS Workstation (Varian, Palo Alto, CA, USA) software data system, version 6.9.
SIM mode was selected and applied for monitoring different ions in each segment. Table 1 shows
the different segments with their time range, m/z selected in each analytical window and the analyte of
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interest to be determined in each case. Peak identification was based on the comparison of retention
times and MS signals with those obtained from the analysis of pure standards.
Table 1. Distribution of the segments used for the selective monitoring of each analyte.
Segment Time Range (min) m/z Selected Analyte
1 4.00–8.98 456–458 7αOHChol
2 8.98–9.64 159, 253, 351 Desm
3 9.64–10.20 213, 255, 353, 443, 456–458 Latho, 7βOHChol
4 10.20–11.31 395–396 Lano
5 11.31–11.99 255, 323, 413, 441 24OHChol
6 11.99–12.25 131 25OHChol
7 12.25–12.70 367, 382, 472, 545 7KetoChol
8 12.70–13.60 161, 255, 417, 456, 546 27OHChol
9 13.60–15.50 189, 203 betulin (IS)
3. Results and Discussion
3.1. Optimization of Detection Conditions
The starting GC conditions were provided by Neuron Bio. Further GC-MS optimization was
carried out in 5 stages to improve the starting conditions. In a first stage of the optimization, each
analyte was individually injected in GC-MS (full scan mode) to determine its retention time and its
characteristic m/z. The values obtained for each analyte and the IS are shown on Table 2. Regarding the
m/z values, it should be noted that the MS signals appear in decreasing order of intensity.
After characterizing the individual behavior of each analyte, we analyzed a multi-standard
solution (full scan mode); an example of the result is provided in Figure 2.
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Figure 2. Chromatogram of a multi-standard solution (20 µg/mL in terms of each standard) to
determine the retention time and the m/z ions of each Chol-related compound. The letters used to refer
to the peaks mean the following: (a) BSTFA/TMS (silylation reagent); (b) 7α-hydroxycholesterol;
(c) cholesterol; (d) desmosterol; (e) lathosterol; (f) 7β-hydroxycholesterol; (g) lanosterol;
(h) 24(S)-hydroxyc terol; (i) 25-hydroxycholest rol; (j) 7-ketocholesterol; (k) 27-hydroxycholesterol;
(l) betulin (IS). The same letter codes are used in the rest of the manuscript.
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Table 2. Retention time (tR) and characteristic m/z signals of cholesterol precursors and oxysterols (in
decreasing order of intensity).
Standard m/z tR (min)
7α-hydroxycholesterol 456, 457 8.73
cholesterol 368, 329, 133, 353, 145 9.14
desmosterol 253, 351, 159, 456 9.49
lathosterol 255, 458, 213, 443, 353 9.74
7β-hydroxycholesterol 456, 457 9.92
lanosterol 395, 396 10.68
24(S)-hydroxycholesterol 145, 323, 413, 159, 441, 255, 546 11.82
25-hydroxycholesterol 131, 145 12.17
7-ketocholesterol 472, 367, 382, 545, 161 12.40
27-hydroxycholesterol 456, 417, 161, 546, 255, 441, 129 13.06
betulin (IS) 189, 203, 496 14.47
It is well known that the concentration of cholesterol is quite high in plasma samples; therefore, to
simulate a real biological situation, we prepared a standard solution containing 2000 µg/mL of Chol
(cholesterol is the most abundant sterol in human plasma with levels in the order of 1 to 3 mg/mL [20])
and 5 µg/mL of the rest of the analytes, which is enough to view the analytes with full scan mode.
The result is illustrated in Figure 3, which shows that Desm (which elutes just after Chol) was properly
detected even with very high concentration levels of Chol in the sample under study. However, Figure 3
also shows that when Chol was present at high concentrations, the signal of the other analytes was
very low in comparison, which hampered their appropriate determination. Another issue related to
Chol concentration is that the peak corresponding to 7α-hydroxycholesterol was hardly detectable.
Thus, the next step of the optimization focused on improving the conditions of ion detection with MS
through the use of SIM mode.
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We selected SIM operational mode and created specific segments or analytical windows (Table 1)
in order to better detect each analyte (using specific MS parameters and looking for the characteristic
m/z signals). A multi-standard solution containing 10 µg/mL of each analyte was injected into the
GC-MS system (SIM mode). The result is shown in Figure 4.
As stated before, IT was used as mass analyzer. Even though IT can be used to perform MS/MS
experiments, the use of SIM mode was selective enough to properly detect and quantify the compounds
under study.
As a result, 9 analytes of interest plus the IS were detected separately by using 9 specific segments.
The segments were optimized and defined taking into account the information included in Table 2
(i.e., retention times and m/z responses). The transfer and detection parameters were optimized aiming
for the maximum sensitivity with the highest possible resolution. SIM led to very promising results
in terms of improvement of the signal-to-noise ratio (S/N), sensitivity, detection and quantification
limits, and some other important analytical validation characteristics.
After optimizing the GC-MS conditions, some biological samples were injected to prove the
suitability of the new methodology in relatively long sequences (including biological samples, which
are sometimes considerably dirty).
After 25 analyses, the need of a pre-column was quite evident to reduce the noise, which increased
when a great number of consecutive injections and chromatographic runs were carried out. A silica
phase with the same internal diameter as the column (0.25 mm) was selected. The pre-column had
1 m length and was connected to the column with press-fit connections. Once the pre-column was
installed the S/N remained constant. The information provided in Table 2 regarding retention time
was achieved with the pre-column already connected to the system.
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Figure 4. Result of analyzing a mix of the analytes under study (plus IS) at a concentration of
10 µg/mL using the segments created. Compounds determined in each segment (segment numbers
are shown on the left side of the figure): (1) 7α-hydroxycholesterol; (2) desmosterol; (3) lathosterol
and 7β-hydroxycholesterol; (4) lanosterol; (5) 24(S)-hydroxycholesterol; (6) 25-hydroxycholesterol;
(7) 7-ketocholesterol; (8) 27-hydroxycholesterol; and (9) betulin (IS). Letter codes are the same as in Figure 2.
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3.2. Validation of the Developed Method
Multi-standard solutions and QC samples were used to validate the method. Table 3 shows all
the analytical parameters calculated during the validation of the developed method [37,38].
Multi-standard solutions were prepared at different concentration levels (0.1, 0.2, 0.5, 1.0, 2.5, and
5.0 µg/mL of each analyte) to build the calibration curves. Forty µg/mL of betulin (as for the biological
samples) were added to each multi-standard solution. Fifty µL of the multi-standard solution were
transferred to a vial containing a 250 µL insert. The solvent was then evaporated with N2, after
which an aliquot of 50 µL of derivatization reagent was added. The reaction mixture was left at room
temperature for 1 h.
Calibration curves, one for each Chol-related compound, were fitted by least-squares regression
from relative area signal (area_Chol-related analyte/area_IS) vs. Chol-related analyte concentration.
The intercept was estimated as zero for all the analytes. For this reason, the relative areas were directly
proportional to the concentration of each analyte. Thus, it was possible to calculate a response factor
(RF) for each compound, which was constant and independent of the concentration of each analyte;
values are shown in Table 3. Each point of the calibration graph corresponded to the mean value of
four independent injections.
Determination coefficients and linearity indices (LIN) [39] were calculated for each calibration
curve to assess goodness of fit. LIN = 1 − (SDslope/slope) is included in Table 3 and was above 98% in
all the cases, except for 25OHChol (96.5%), which had a slightly higher detection limit. Therefore, it
was not possible to detect low concentrations.
The calibration curve, response factor, and linearity index were calculated considering the four
replicates of each concentration level of the multi-standard solutions injected.
Table 3. Analytical parameters obtained during the validation of the method.














7αOH Chol 0.115 98.2 0.01 0.03 83.8 97.3 0.106 0.200
Desm 0.013 98.7 0.01 0.03 74.2 96.9 0.073 0.166
Latho 0.025 98.0 0.12 0.37 67.7 104.8 0.088 0.277
7βOH Chol 0.100 98.8 0.01 0.03 67.0 100.1 0.159 0.271
Lano 0.040 98.6 0.02 0.07 72.7 98.0 0.148 0.170
24OH Chol 0.0053 98.0 0.14 0.44 71.0 96.5 0.181 0.228
25OH Chol 0.022 96.5 0.35 1.06 97.8 99.4 0.146 0.294
7Keto Chol 0.020 97.9 0.07 0.20 73.2 95.5 0.114 0.197
27OH Chol 0.023 98.5 0.02 0.07 65.8 97.7 0.059 0.203
Limit of detection (LOD) and limit of quantification (LOQ) were determined considering the
standard deviation calculated from six replicates of the lower sample concentration and multiplying
it by 3.28 and 10, respectively. The 3.28 value is the 95%-quantile of the non-centrally t-distribution
with ∞ degrees of freedom (α = β = 0.05) [40]. Detection and quantification limits for 25OHChol were
slightly higher than for the rest of the analytes, which can be explained because only one m/z signal
was characteristic for this analyte; therefore, its determination was not as selective as that of the others.
7αOHChol, 7βOHChol, and Desm exhibited the lowest detection and quantification limits, with 0.01
and 0.03 µg/mL, respectively, in three cases.
Spiked goat serum samples were prepared to test the matrix effect and control the repeatability of
the overall analytical process. To verify the matrix effect, calibration curves were prepared by spiking
goat serum after the extraction with the Chol-related compounds (samples codes: QC00-05, QC00-10,
QC00-25, QC00-50) at different levels: 0.5, 1.0, 2.5, and 5.0 µg/mL. The slopes of these calibration
curves were compared with those achieved by using external standard calibration. The native levels
of analytes present in the goat blood serum sample (QC00) were previously determined in order to
perform an effective blank correction. In QC00, the following compounds were found: 7αOHChol,
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7βOHChol, 24OHChol, and 7KetoChol. The other Chol-related compounds were not detected
(nd; below the detection limit). The area values found for this sample were considered in all the
subsequent calculations and were subtracted from the values achieved after spiking with the known
concentration levels to assess the matrix effect. Such concentration levels were QC00-05 (spiked with
0.5 µg/mL of multi-standard solution), QC00-10 (spiked with 1.0 µg/mL of multi-standard solution),
QC00-25 (spiked with 2.5 µg/mL of multi-standard solution), and QC00-50 (spiked with 5.0 µg/mL of
multi-standard solution). As shown on Table 3, matrix effect recoveries were found between 95.5%
and 104.8% for 7KetoChol and Latho, respectively (100% was the value that would be achieved if the
slopes of the external standard calibration and standard addition calibration curves were identical); in
other words, the matrix effect was not observed in the current study.
Moreover, to provide an estimation of overall repeatability (including sample preparation and
measurement), goat serum samples spiked with the Chol-related analytes under study—before the
extraction—were prepared at the same levels as shown above (samples codes: QC 05, QC 10, QC 25, and
QC 50). The standard deviation (SD) was calculated from four consecutive measurements; to estimate
the repeatability of the overall process, SD was calculated from three independent goat serum samples
that were extracted, injected, and analyzed separately. The average SD of the determined values is
provided in Table 3 and was found to be within 0.059–0.181 for repeatability of the measurements and
0.166–0.294 for the overall process.
The same preparations were useful to assess the recovery factor. The theoretical added concentration
did not exactly coincide with the concentration obtained after the extraction and the corresponding
measurement. Given that no matrix effect was observed in the previous step, we concluded that the
difference was due to the recovery (obviously lower than 100%). Recovery values were calculated and
are shown in Table 3: they ranged from 65.8% to 97.8% for 27OHChol and 25OHChol, respectively.
These recovery factors should be used to calculate the real concentration of each analyte in any biological
sample. They were applied to obtain the quantitative values shown in Table 4.
Table 4. Concentration levels found for each Chol-related compound in the test samples. The concentration
was recalculated applying the appropriate recovery factor.












Average (µg/mL) 0.76 0.25 d (0.13) 0.80 nd 1.28 nd 2.92 0.39
RSD (%) 5.51 30.08 33.67 0.89 - 14.75 - 3.90 14.74
TA2
Average (µg/mL) 0.22 0.28 0.46 0.41 nd 1.06 nd 1.62 0.87
RSD (%) 3.80 31.19 22.59 18.89 - 8.50 - 8.10 33.02
TA3
Average (µg/mL) 0.70 0.39 0.39 0.76 nd 0.99 nd 2.99 0.84
RSD (%) 9.48 7.61 27.30 9.16 - 11.98 - 9.14 22.16
TB1
Average (µg/mL) 0.14 0.19 0.49 0.19 nd 0.76 nd d (0.17) 0.51
RSD (%) 19.53 30.19 21.59 21.76 - 17.01 - 27.23 26.05
TB2
Average (µg/mL) 0.42 nd d (0.19) 0.35 nd 2.01 nd 1.70 0.42
RSD (%) 0.24 - 30.19 10.11 - 13.94 - 11.17 10.57
TB3
Average (µg/mL) 0.11 nd nd 0.11 nd 1.04 nd 0.53 0.35
RSD (%) 5.24 - - 11.97 - 1.36 - 9.00 28.14
TC1
Average (µg/mL) 0.061 nd nd 0.04 nd 0.72 nd d (0.16) 0.26
RSD (%) 9.74 - - 10.26 - 20.86 - 11.56 23.14
TC2
Average (µg/mL) 0.15 nd d (0.20) 0.13 nd 0.85 nd 0.87 0.24
RSD (%) 5.33 - 29.67 22.95 - 19.91 - 2.01 30.00
TC3
Average (µg/mL) 0.057 nd d (0.34) d (0.016) nd 0.98 nd 0.56 0.31
RSD (%) 1.99 - 24.09 21.72 - 19.98 - 21.57 22.01
RSD: Relative standard deviation; nd: not detected; d: detected, but below LOQ (in parentheses, when the value is
<LOQ, a rough estimation is given).
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3.3. Application of the Method to the Analysis of Biological Samples
Biological test samples were used for the application of the method. Each test sample was
prepared and injected four times. Figure 5 shows an example of the results achieved for a mouse
plasma sample (TA2) by using the SIM method with the 9 optimized segments.
In this example, all the selected analytes were found, with the exception of Lano (segment 4) and
25OHChol (segment 6); both analytes were indicated as not detected. In addition, some Chol-related
compounds were detected but not quantified (they were below the LOQ). This was the case of Latho
in samples TA1, TB1, TC2, and TC3 and 7KetoChol in samples TB1 and TC1. The rest of the analytes
were found at concentration levels above their LOQs.
Quantitative results are summarized in Table 4, which includes the average concentration (µg/mL)
of each analyte and the relative standard deviation (%RSD). The recovery factor was used to recalculate
the real analyte concentration after extraction.
As stated above, there were three types of mice (A, B, and C) and three specimens in each group
(1, 2, and 3). Samples belonging to the same group did not always show very similar results, what
could be easily explained considering the fact that we studied different specimens.
Lano and 25OHChol were not detected in any sample. Desm was only detected in TA samples
(TA1, TA2, and TA3) with concentration values ranging from 0.25 to 0.39 µg/mL, and in TB1, with a
value of 0.19 µg/mL. Latho was found in the three specimens of Type A mice, with amounts of 0.39 and
0.46 µg/mL (TA3 and TA2); it was detected but not quantified in TA1. It was also found in two specimens
of Type B mice (TB1 and TB2), with concentration values of 0.49 and 0.19 µg/mL respectively (the latter
was a rough estimation), and in two Type C mice samples (estimated values—concentrations below
LOQ—of 0.20 and 0.34 µg/mL—samples TC2 and TC3) (see Table 2). Overall, the rest of Chol-related
compounds showed a decreasing trend in terms of concentration levels in mice A, B, and C.
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Results showed that 7αOHChol was found at higher concentrations in Type A mice with the
following values: 0.76, 0.22, and 0.70 µg/mL. In Type B samples, however, concentration values were
0.14, 0.42, and 0.11 µg/mL in the three specimens respectively. Type C mice showed the lowest values,
ranging from 0.057 to 0.15 µg/mL. The situation was similar for 7βOHChol: the highest values were
obtained for Type A mice (0.80, 0.41, and 0.76 µg/mL). 27OHChol and 24OHChol were found in
all the samples. Their highest levels were determined in TA2 (0.87 µg/mL of 27OHChol), and TB2
(2.01 µg/mL of 24OHChol). As 24OHChol (also known as cerebrosterol) is a cholesterol catabolite
produced almost exclusively in the brain, a reduction in its plasma levels after treatment with statins is
regarded as an indirect marker of the inhibitory effect of these statins on brain cholesterol biosynthesis.
7KetoChol was found in all samples except for TB1 and TC1, in which it was detected but not
quantified. In this case, its highest levels were determined in TA3 (2.99 µg/mL of 7KetoChol).
Overall, Type C mice showed a lower concentration of all Chol-related compounds, followed by
Type B mice and Type A mice, which tended to exhibit the highest concentration values. These results
are consistent with the fact that Type C mice were fed with statin. Several studies have pointed at a
relationship between treatment with statins and a reduction of the risk of developing Alzheimer’s
disease [41–44]. This can be explained considering that statins can help to reduce oxysterol levels,
which affect amyloid beta production. Our findings indicate that a statin-rich diet can affect the brain
cholesterol metabolism of mice to a certain extent; further studies are still needed to clarify whether
the use of statins can be a useful strategy for treating the onset of clinical dementia, but promising
results can already be found in the literature.
4. Conclusions
This study proves that GC-(IT)MS, working in SIM mode, is an analytical platform suitable
to detect and quantify cholesterol precursors and oxysterols in mouse plasma samples. The high
cholesterol concentration present in this biological fluid may impede the proper detection of the
chromatographic peaks of some Chol-related compounds that were eluting close to the cholesterol
peak; however, this potential issue was avoided by using the SIM mode. The use of a GC pre-column
was another methodological improvement tested in this study. We demonstrated that it can easily
reduce the background noise usually found in the biological samples; this strategy also extends the
lifetime of the analytical column.
Other chromatography–MS methods have been reported in the literature, showing even better
performance characteristics. Yet, this study proves that the proposed method is fit for monitoring the
contents of some AD biomarkers in plasma samples from mammals that are used as experimental
animals. Sample selection in this study was very special as it included non-transgenic and transgenic
mice that were fed different diets. Overall, Type C mice (i.e., transgenic mice fed with statin) showed
a lower concentration of every Chol-related compound; this fact may be explained considering that
statins can help to reduce oxysterols levels, which affect amyloid beta production. We consider
the results to be very promising, however, we are aware about some limitations of our study;
several experiments are already under way to increase the number of samples analyzed and
ensure that the observed variations in measurements are due to the treatment and not to potential
population variability.
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